Thermalin Diabetes is developing clinically-superior, second generation insulin analogs for the rapidly growing $12 billion insulin market.
Thermalin’s patent pending compounds include rapid-, intermediate- and long-acting analogs. With patents expiring on existing analogs in the next three to four years, Thermalin looks to form partnerships with large pharmaceutical companies that wish to market superior, next generation insulin therapies.
Thermalin Diabetes, LLC is a JumpStart portfolio company. The investment came from the JumpStart Evergreen Fund.